Pasar al contenido principal

DESARROLLO DE NUEVAS HERRAMIENTAS DIAGNOSTICAS Y ESTRATEGIAS TERAPEUTICAS PARA LA ENFERMEDAD DE ALZHEIMER: UN ENFOQUE DE IMAGEN MULTIMODAL

PID2020-117656RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario ASOCIACIÓN CENTRO DE INVESTIGACION COOP. BIOMATERIALES

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Urease-powered nanobots for radionuclide bladder cancer therapy

  • Simó, Cristina|||0000-0002-5980-9379
  • Serra-Casablancas, Meritxell|||0000-0003-4806-3249
  • Hortelão, A. C. L.|||0000-0001-9269-0480
  • Di Carlo, Valerio|||0000-0002-5099-0685
  • Guallar Garrido, Sandra|||0000-0002-9666-5757
  • Plaza-García, Sandra
  • Rabanal Prados, Rosa Ma|||0000-0002-9521-791X
  • Ramos-Cabrer, Pedro|||0000-0003-0368-7031
  • Yagüe, Balbino
  • Aguado, Laura
  • Bardia, Lídia
  • Tosi, Sébastien
  • Gómez Vallejo, Vanessa|||0000-0003-3995-9596
  • Martín, Abraham
  • Patiño, Tania|||0000-0001-9979-7926
  • Julián, Esther|||0000-0002-6558-3978
  • Colombelli, Julien|||0000-0002-2784-4276
  • Llop, Jordi|||0000-0002-0821-9838
  • Sánchez Ordóñez, Samuel|||0000-0001-9713-9997
Bladder cancer treatment via intravesical drug administration achieves reasonable survival rates but suffers from low therapeutic efficacy. To address the latter, self-propelled nanoparticles or nanobots have been proposed, taking advantage of their enhanced diffusion and mixing capabilities in urine when compared with conventional drugs or passive nanoparticles. However, the translational capabilities of nanobots in treating bladder cancer are underexplored. Here, we tested radiolabelled mesoporous silica-based urease-powered nanobots in an orthotopic mouse model of bladder cancer. In vivo and ex vivo results demonstrated enhanced nanobot accumulation at the tumour site, with an eightfold increase revealed by positron emission tomography in vivo. Label-free optical contrast based on polarization-dependent scattered light-sheet microscopy of cleared bladders confirmed tumour penetration by nanobots ex vivo. Treating tumour-bearing mice with intravesically administered radio-iodinated nanobots for radionuclide therapy resulted in a tumour size reduction of about 90%, positioning nanobots as efficient delivery nanosystems for bladder cancer therapy. Bladder cancer treatment suffers from low therapeutic efficacy. Here the authors present radioactive 131 I-labelled urease-powered nanobots that exhibit enhanced accumulation at the tumour site, enabling effective radionuclide therapy at low doses as an alternative treatment option for bladder cancer.
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

PET Imaging of Self-Assembled 18F-Labelled Pd2L4 Metallacages for Anticancer Drug Delivery

  • Cosialls, Raúl
  • Simó, Cristina
  • Borrós, Salvador
  • Gómez Vallejo, Vanessa
  • Schmidt, Claudia
  • Llop, Jordi
  • Cuenca, Ana Belen
  • Casini, Angela
To advance the design of self-assembled metallosupramolecular architectures as new generation theranostic agents, the synthesis of 18F-labelled [Pd2L4]4+ metallacages is reported. Different spectroscopic and bio-analytical methods support the formation of the host-guest cage-cisplatin complex. The biodistribution profiles of one of the cages, alone or encapsulating cisplatin have been studied by PET/CT imaging in healthy mice in vivo, in combination to ICP-MS ex vivo., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Multimodal imaging of the role of hyperglycemia following experimental subarachnoid hemorrhage

  • Joya, Ana
  • Plaza-García, Sandra
  • Padro, Daniel
  • Aguado, Laura
  • Iglesias, Leyre
  • Garbizu, Maider
  • Gómez-Vallejo, Vanessa
  • Laredo, Carlos
  • Cossío, Unai
  • Torné, Ramon
  • Amaro, Sergio
  • Planas, Anna M.
  • Llop, Jordi
  • Ramos-Cabrer, Pedro
  • Justicia, Carles
  • Martín, Abraham
Hyperglycemia has been linked to worsening outcomes after subarachnoid hemorrhage (SAH). Nevertheless, the mechanisms involved in the pathogenesis of SAH have been scarcely evaluated so far. The role of hyperglycemia was assessed in an experimental model of SAH by T2 weighted, dynamic contrast-enhanced magnetic resonance imaging (T2W and DCE-MRI), [18F]BR-351 PET imaging and immunohistochemistry. Measures included the volume of bleeding, the extent of cerebral infarction and brain edema, blood brain barrier disruption (BBBd), neutrophil infiltration and matrix metalloprotease (MMP) activation. The neurofunctional outcome, neurodegeneration and myelinization were also investigated. The induction of hyperglycemia increased mortality, the size of the ischemic lesion, brain edema, neurodegeneration and worsened neurological outcome during the first 3 days after SAH in rats. In addition, these results show for the first time the exacerbating effect of hyperglycemia on in vivo MMP activation, Intercellular Adhesion Molecule 1 (ICAM-1) expression and neutrophil infiltration together with increased BBBd, bleeding volume and fibrinogen accumulation at days 1 and 3 after SAH. Notably, these data provide valuable insight into the detrimental effect of hyperglycemia on early BBB damage mediated by neutrophil infiltration and MMP activation that could explain the worse prognosis in SAH., The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by grants from the Spanish Ministry of Education and Science/FEDER RYC-2017-22412, and PID2019-107989RB-I00, PID2020-118546RB-I00 and La Marató de TV3 (17/C/2017) and by Instituto de Salud Carlos III (PI19/00936, co-funded by the European Regional Development Fund). Jordi Llop also acknowledges the Spanish Research Agency for financial support (MCIN/AEI/10.13039/501100011033; PID2020-117656RB-I00). Part of the work was performed under the Maria de Maeztu Units of Excellence Programme – Grant MDM-2017-0720 funded by MCIN/AEI/10.13039/501100011033. This work was also performed thanks to the human and technical equipment of the Magnetic Resonance Imaging Core facility at IDIBAPS (IBPS15-EE-3688 co-funded by MCIU and by ERDF)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Preclinical validation of human recombinant glutamate-oxaloacetate transaminase for the treatment of acute ischemic stroke

  • Pérez-Mato, María
  • Dopico-López, Antonio
  • Akkoc, Yunus
  • López-Amoedo, Sonia
  • Correa-Paz, Clara
  • Candamo-Lourido, María
  • Iglesias-Rey, Ramón
  • López-Arias, Esteban
  • Bugallo-Casal, Ana
  • da Silva-Candal, Andrés
  • Bravo, Susana B
  • Chantada-Vázquez, María Del Pilar
  • Arias, Susana
  • Santamaría-Cadavid, María
  • Estany-Gestal, Ana
  • Zaghmi, Ahlem
  • Gauthier, Marc A
  • Gutiérrez-Fernández, María
  • Martin, Abraham
  • Llop Roig, Jordi
  • Rodríguez González, Cristina
  • Almeida, Ángeles
  • Migliavacca, Martina
  • Polo, Ester
  • Pelaz, Beatriz
  • Gozuacik, Devrim
  • El Yamani, Naouale
  • SenGupta, Tanima
  • Rundén-Pran, Elise
  • Vivancos, José
  • Castellanos, Mar
  • Díez-Tejedor, Exuperio
  • Sobrino, Tomás
  • Rabinkov, Aharon
  • Mirelman, David
  • Castillo, José
  • Campos, Francisco
The blood enzyme glutamate-oxaloacetate transaminase (GOT) has been postulated as an effective therapeutic to protect the brain during stroke. To demonstrate its potential clinical utility, a new human recombinant form of GOT (rGOT) was produced for medical use. We tested the pharmacokinetics and evaluated the protective efficacy of rGOT in rodent and non-human primate models that reflected clinical stroke conditions. We found that continuous intravenous administration of rGOT within the first 8 h after ischemic onset significantly reduced the infarct size in both severe (30%) and mild lesions (48%). Cerebrospinal fluid and proteomics analysis, in combination with positron emission tomography imaging, indicated that rGOT can reach the brain and induce cytoprotective autophagy and induce local protection by alleviating neuronal apoptosis. Our results suggest that rGOT can be safely used immediately in patients suspected of having a stroke. This study requires further validation in clinical stroke populations., This study was supported by the Instituto de Salud Carlos III_ICIII (grant numbers ICI19/00032, PI20/01014, AC19/00066, and the RICORS-ICITUS network: RD21/0006/0003), Xunta de Galicia (grant number IN607D2020/03), the European Union program FEDER, and the European Regional Development Fund. This study was partially supported under the framework of EuroNanoMed III. A.Z. acknowledges a doctoral scholarship from the INRS/Tunisian Ministry of Education. M.A.G. is a Research Scholar of the Fonds de Recherche du Québec Santé (FRQS, Canada). J.L. thanks the grant AEI-MICINN/PID2020-117656RB-I00. F.C., T.S., and M.G.-F. declare ISCIII Miguel Servet contracts (CPII19/00020, CPII17/00027, and CPII20/0002, respectively). M.P.-M. and A.d.S.-C. declare an ISCIII Sara Borrell contract (CD19/00033 and CD20/00054, respectively). A.M. declare a Ramon y Cajal contract (RYC-2017-22412). B.P. thanks the support of the European Research Council (starting grant #950421) and the Xunta de Galicia (ED431F 2021/02, 2023-PG056, and Centro Singular De Investigación de Galicia Accreditation 2019–2022 (#ED431G 2019/03)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

PET Imaging of Self-Assembled 18F-Labelled Pd2L4 Metallacages for Anticancer Drug Delivery

  • Cosialls, Raúl
  • Simó, Cristina
  • Borrós, Salvador
  • Gómez Vallejo, Vanessa
  • Schmidt, Claudia
  • Llop, Jordi
  • Cuenca, Ana B.
  • Casini, Angela
To advance the design of self-assembled metallosupramolecular architectures as new generation theranostic agents, the synthesis of 18F-labelled [Pd2L4]4+ metallacages is reported. Different spectroscopic and bio-analytical methods support the formation of the host-guest cage-cisplatin complex. The biodistribution profiles of one of the cages, alone or encapsulating cisplatin have been studied by PET/CT imaging in healthy mice in vivo, in combination to ICP-MS ex vivo., info:eu-repo/semantics/publishedVersion